In samples from patients with B-ALL and DLBCL, we also detected heightened levels of Bcl-3 expression along with the enrichment of various pathways, such as NFκB immune response PI3K/AKT/mTOR, IL-6, and TGF-β signaling pathways. This evidence concerns the gene BCL3 and diffuse large B-cell lymphoma.